New — Free Peptide Starter Guide (2026): 13 chapters, 34 cited studies

Get it free
ToolsCompareAICAR vs Vesugen

AICAR vs Vesugen

Side-by-side comparison of key properties, dosing, and research.

Anti-Aging & LongevityFat Loss & Metabolic
AICAR
Anti-Aging & Longevity
Vesugen
Summary
AICAR is a cell-permeable AMP analog that activates AMPK (AMP-activated protein kinase) — the master metabolic switch that triggers fat burning, mitochondrial biogenesis, and adaptations normally only achieved through exercise. It has been called the 'exercise in a pill' compound.
Vesugen is a tripeptide bioregulator (Lys-Glu-Asp) developed by Professor Vladimir Khavinson, tissue-specific for blood vessels and the vascular endothelium. It supports endothelial cell function, promotes vascular wall integrity, and is studied for atherosclerosis prevention, vascular aging, and cardiovascular health maintenance. It is one of the more broadly applicable Khavinson bioregulators given the ubiquity of vascular tissue.
Half-Life
~2–3 hours
Short (minutes); sustained gene-regulatory effects
Admin Route
SubQ, IV
SubQ, Oral
Research
Typical Dose
25–50 mg
10 mg per day
Frequency
3–5 times per week
Daily for 10–30 days
Key Benefits
  • AMPK activation mimics aerobic exercise adaptations
  • Increased fat oxidation and endurance
  • Mitochondrial biogenesis (PGC-1alpha)
  • Improved insulin sensitivity and glucose metabolism
  • Anti-inflammatory effects
  • Potential cardiac protection during ischemia
  • Synergistic with actual exercise training
  • Reduces hepatic glucose production
  • Supports vascular endothelial cell function and integrity
  • May reduce endothelial inflammation and dysfunction
  • Anti-aging effects on blood vessel walls
  • Potential benefits in early atherosclerosis and vascular aging
  • Supports nitric oxide-mediated vascular tone
  • Reduces endothelial apoptosis from oxidative stress
  • Complementary to Cardiogen and Epithalon in cardiovascular longevity protocols
Side Effects
  • Hypoglycemia risk
  • Lactic acidosis at high doses (animal data)
  • Injection site irritation
  • Generally well tolerated
  • Mild injection site reactions
  • No significant vascular adverse events reported at standard doses
Stacks With